Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The prevalence of faecal incontinence in myotonic dystrophy type 1.

Neuromuscular disorders : NMD·2019
Same author

Infantile pemphigoid treated without oral corticosteroids.

Clinical and experimental dermatology·2019
Same author

Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK.

Journal of neurology, neurosurgery, and psychiatry·2015
Same author

Magnetic resonance imaging of facial muscles.

Clinical radiology·2007
Same author

Paraneoplastic limbic encephalitis.

Clinical neurology and neurosurgery·2005
Same author

A limited epidemiological study of seropositive myasthenia gravis in Tayside.

Scottish medical journal·2003
Same journal

Dr Archibald Hewan (1832-1883) and the University of Glasgow's medical libraries.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

Joyce Grainger Learning Centre.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

Features in this issue.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

An unusual case of cutaneous tuberculosis and paradoxical TB in a patient with spondyloarthritis treated with adalimumab.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

Leptospiral infection overlapping with autoimmune hepatitis: A diagnostic conundrum.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

Tocilizumab vs bevacizumab in critically ill COVID-19 patients: Registry-based prospective study.

The journal of the Royal College of Physicians of Edinburgh·2025
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

Myasthenic syndromes.

M E Farrugia1

  • 1Neurology Department, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK. m.e.farrugia@doctors.org.uk

The Journal of the Royal College of Physicians of Edinburgh
|March 3, 2011
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis and Lambert-Eaton myasthenic syndrome involve autoimmune attacks on the neuromuscular junction, causing muscle weakness. Congenital myasthenic syndromes are inherited disorders affecting neuromuscular junction proteins.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Experiment Videos

Last Updated: Jun 4, 2026

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Neurology
  • Immunology
  • Genetics

Background:

  • The neuromuscular junction (NMJ) is a critical interface for muscle contraction, susceptible to autoimmune and genetic disorders.
  • Autoimmune attacks can target the nicotinic acetylcholine receptor (nAChR) causing myasthenia gravis (MG) or voltage-gated calcium channels (VGCCs) causing Lambert-Eaton myasthenic syndrome (LEMS).
  • Congenital myasthenic syndromes (CMS) represent a group of inherited disorders resulting from genetic defects in NMJ proteins.

Purpose of the Study:

  • To differentiate the autoimmune and genetic etiologies of neuromuscular junction disorders.
  • To outline the distinct clinical presentations and pathogenic mechanisms of myasthenia gravis, Lambert-Eaton myasthenic syndrome, and congenital myasthenic syndromes.
  • To discuss current therapeutic strategies for these conditions.

Main Methods:

  • Review of existing literature on the pathophysiology, clinical features, and treatment of NMJ disorders.
  • Comparative analysis of autoimmune markers (anti-nAChR antibodies, anti-VGCC antibodies) and genetic mutations.
  • Correlation of clinical phenotypes with underlying molecular defects.

Main Results:

  • Myasthenia gravis is primarily caused by antibodies against the muscle surface nAChR, leading to generalized or ocular muscle weakness.
  • Lambert-Eaton myasthenic syndrome involves antibodies against pre-synaptic VGCCs, often associated with small cell lung carcinoma and presenting with proximal muscle fatigability and autonomic dysfunction.
  • Congenital myasthenic syndromes result from various genetic mutations affecting NMJ proteins, with diverse clinical phenotypes and no indication for immunosuppression.

Conclusions:

  • Autoimmune neuromuscular junction disorders like MG and LEMS require distinct diagnostic approaches and treatments, including immunosuppression and thymectomy for MG.
  • Congenital myasthenic syndromes are non-autoimmune, inherited conditions managed symptomatically.
  • Understanding the specific etiology of NMJ dysfunction is crucial for effective patient management.